1-6 of 6
Michael S. Katz, BS
Close
Sort by
Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up

Noa Biran, MD, Susanna Jacobus, David Siegel, MD PhD, Natalie Scott Callander, MD, Rafael Fonseca, MD, David H. Vesole, MD, Michael E. Williams, MD, Rafat Abonour, MD, Michael S Katz, BS,MBA, S. Vincent Rajkumar, Philip R. Greipp, MD
Journal: Blood
Blood (2015) 126 (23): 3174.
https://doi.org/10.1182/blood.V126.23.3174.3174
Published: 2015
Journal Articles

Development of the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) Scale and Validation in the Eastern Cooperative Oncology Group Trial E1A05,

Matthias Weiss, MD, PhD, Susanna Jacobus, MS, Lynne I Wagner, PhD, David Cella, PhD, Michael S Katz, BS., MBA, Vincent Rajkumar, MD, Rafael Fonseca, MD
Journal: Blood
Blood (2011) 118 (21): 4184.
https://doi.org/10.1182/blood.V118.21.4184.4184
Published: 2011
Journal Articles

Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial

David Samuel diCapua Siegel, MD, PhD, Susanna Jacobus, MS, S. Vincent Rajkumar, MD, Rafat Abonour, MD, Natalie Scott Callander, MD, Michael S Katz, BS., MBA, Rafael Fonseca, David H. Vesole, MD, PhD, On behalf of the Eastern Cooperative Oncology Group
Journal: Blood
Blood (2010) 116 (21): 38.
https://doi.org/10.1182/blood.V116.21.38.38
Published: 2010
Journal Articles

Oral Antibiotic Prophylaxis of Early Infection In Multiple Myeloma: A URCC/ECOG Phase III Study

David H. Vesole, MD, PhD, Martin M Oken, MD, Charles Heckler, Philip R. Greipp, MD, Michael S Katz, BS., MBA, Susanna Jacobus, MS, Gary R Morrow, PhD, MS, On Behalf of the University of Rochester Cancer Center and the Eastern Cooperative Oncology Group
Journal: Blood
Blood (2010) 116 (21): 3017.
https://doi.org/10.1182/blood.V116.21.3017.3017
Published: 2010
Journal Articles

Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)

David H. Vesole, MD, PhD, Susanna Jacobus, MS, S. Vincent Rajkumar, MD, Rafat Abonour, MD, Natalie Scott Callander, MD, Philip R. Greipp, MD, Rafael Fonseca, Michael S Katz, BS., MBA, David Samuel diCapua Siegel, MD, PhD, On Behalf of the Eastern Cooperative Oncology Group
Journal: Blood
Blood (2010) 116 (21): 308.
https://doi.org/10.1182/blood.V116.21.308.308
Published: 2010
Journal Articles

Genetic Polymorphisms Identify the Likelihood of Bone Disease in Myeloma: Correlations with Myeloma Cell DKK1 Expression and High Risk Gene Signatures.

Brian G.M. Durie, MD, Brian Van Ness, PhD, Christine Ramos, PhD, Owen Stephens, Majda Haznadar, Antje Hoering, PhD, Jeff Haessler, PhD, Michael S. Katz, BS, Gregory R. Mundy, MD, Robert A. Kyle, MD, Gareth J. Morgan, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, John Shaughnessy, Jr., PhD
Journal: Blood
Blood (2007) 110 (11): 816.
https://doi.org/10.1182/blood.V110.11.816.816
Published: 2007